New Trial to Study Asthma Drug Responses, Genetic Factors in African-Americans | GenomeWeb

NEW YORK (GenomeWeb News) — The National Heart, Lung, and Blood Institute has launched a multi-site clinical trial to assess how African-Americans with asthma respond to different therapies, and to examine the genetics at play in those responses, NHLBI said today.

The Best African American Response to Asthma Drugs (BARD) study will enroll roughly 500 children and adults at 30 sites in 14 states to research their responses to varying combinations of medications and dosages and how genes may affect those responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.